View ValuationVeradermics 향후 성장Future 기준 점검 0/6Veradermics (는) 각각 연간 54.9% 및 63.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 106.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -13% 로 예상됩니다.핵심 정보54.9%이익 성장률106.59%EPS 성장률Pharmaceuticals 이익 성장14.4%매출 성장률63.1%향후 자기자본이익률-13.01%애널리스트 커버리지Low마지막 업데이트13 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates속보 • May 13Veradermics Advances Oral Hair Loss Program With Positive Results and $766.8 Million FundingVeradermics reported positive Phase 2/3 topline results for its oral hair-loss candidate VDPHL01 in Study 302, supporting its potential as the first FDA-approved oral treatment for pattern hair loss in almost 30 years. The company completed enrollment in pivotal Phase 3 Study 304 in male pattern hair loss and continues to enroll patients in Phase 3 Study 306 in female pattern hair loss. Veradermics raised about $766.8 million through its IPO and follow-on offerings, which the company expects to use to fund operations into 2030 and advance its clinical programs. The combination of positive late-stage data and multiple ongoing Phase 3 programs places Veradermics at a key development point where regulatory and clinical decisions may become major value drivers. For investors, the sizeable cash position reduces near-term financing risk, while outcomes for VDPHL01 and future regulatory interactions remain central uncertainties to watch.공시 • Apr 30+ 1 more updateVeradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million.Veradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,843,790 Price\Range: $100공시 • Apr 28Veradermics, Incorporated has filed a Follow-on Equity Offering.Veradermics, Incorporated has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000Seeking Alpha • Apr 28Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline ThesisSummary Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE’s late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01’s regulatory approval and commercialization as a first-in-class oral therapy. A strong cash position post-offering supports Phase 3 completion; execution on VDPHL01 is central to valuation and future stock momentum. Read the full article on Seeking Alpha공시 • Feb 10Veradermics, Incorporated Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair LossVeradermics, Incorporated announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this milestone marks the completion of enrollment across both Phase 3 clinical trials of VDPHL01 in males, encompassing more than 1,000 participants. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements regarding the timing of completion of and data from the Phase 3 clinical trials for VDPHL01 for thetreatment of male and female pattern hair loss; the release profile of VDPHL01 and whether the release profile will achieve its intended effect; whether Veradermics will successfully file a new drug application for VDPHL01; and the projected size of the market for pattern hair loss treatments. Veradermics' anticipation that its success will depend on the approval and successful commercialization of VDPHL01, which is its lead product candidate, and if Veradermics is unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any other current or future product candidates, or experience significant delays in doing so, its business will be materially harm; risks related to preclinical and clinical development and that results of earlier studies and trials may not be predictive of future preclinical studies or clinical trial results; the risk that Veradermics may encounter substantial delays in preclinical and clinical trials, or may not be able to conduct or complete preclinical or clinical trials on the expected timelines, if at all; the risk that the U.S. Food and Drug Administration does not conclude that VDPHL01 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for VDPHL01 under Section 505(b)(2") are not as Veradermics expects, the approval pathway for those product candidates takes longer or costs more than anticipated; the risk that adverse events or undesirable side effects are caused by Veradermics' product candidates; competition from other companies; risks related to developing Veradermics' sales, marketing and distribution capability; the risk that even if Veradermics obtains regulatory approval for VDPHL01 or any other product candidates, such products may fail to achieve market acceptance; the risk that the commercial opportunity for VDPHL01 or Any other current or future product candidates may be smaller than Veradermics expects; the cash-pay healthcare market for VDPHL01 may limit Veradermics' ability to increase sales or achieve profitability; risks relating to effectively maintaining, promoting and enhancing Veradermics' reputation and VDPHL01 brand recognition in a cost-effective manner; risks related to Veradermics' need to grow its organization; the ability of Veradermics to successfully execute its intellectual property strategy for VDPHL01 and risks related to Veradermic' need to grow its organization. the ability of Veradermic to successfully execute its intellectual property strategies for VDPHL01 and risk related to Veradermics's ability to obtain and maintain sufficient intellectual property protection for VDPHL01 and other current and any future product candidates and other proprietary technologies; risks related to ongoing regulatory obligations for any approved products; risks related to Verader mics' reliance on third parties for the manufacture of drug or biological substances for preclinical studies and clinical trials and expectations that Veradermics will continue to do so for commercialization of any product candidates that are approved for marketing; risks related to VeraderMics' reliance and expected continued reliance on third parties to conduct preclinical studies and clinical trials; global macro conditions; global macro and regulatory obligations for any approved products.공시 • Feb 04Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million.Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,077,647 Price\Range: $17 Transaction Features: Sponsor Backed Offering이익 및 매출 성장 예측NYSE:MANE - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028168-116-105N/A312/31/202717-101-103N/A312/31/2026N/A-119-107N/A43/31/2026N/A-98N/AN/AN/A12/31/2025N/A-83-72-72N/A9/30/2025N/A-62-52-52N/A12/31/2024N/A-27-24-24N/A애널리스트 향후 성장 전망수입 대 저축률: MANE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: MANE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: MANE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: MANE 은(는) 내년에 수익이 없을 것으로 예상됩니다.고성장 매출: MANE 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MANE의 자본 수익률은 3년 후 -13%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/14 21:22종가2026/05/14 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Veradermics, Incorporated는 4명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Prakhar AgrawalCantor Fitzgerald & Co.Geoffrey MeachamCitigroup IncRoger SongJefferies LLC1명의 분석가 더 보기
속보 • May 13Veradermics Advances Oral Hair Loss Program With Positive Results and $766.8 Million FundingVeradermics reported positive Phase 2/3 topline results for its oral hair-loss candidate VDPHL01 in Study 302, supporting its potential as the first FDA-approved oral treatment for pattern hair loss in almost 30 years. The company completed enrollment in pivotal Phase 3 Study 304 in male pattern hair loss and continues to enroll patients in Phase 3 Study 306 in female pattern hair loss. Veradermics raised about $766.8 million through its IPO and follow-on offerings, which the company expects to use to fund operations into 2030 and advance its clinical programs. The combination of positive late-stage data and multiple ongoing Phase 3 programs places Veradermics at a key development point where regulatory and clinical decisions may become major value drivers. For investors, the sizeable cash position reduces near-term financing risk, while outcomes for VDPHL01 and future regulatory interactions remain central uncertainties to watch.
공시 • Apr 30+ 1 more updateVeradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million.Veradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,843,790 Price\Range: $100
공시 • Apr 28Veradermics, Incorporated has filed a Follow-on Equity Offering.Veradermics, Incorporated has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000
Seeking Alpha • Apr 28Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline ThesisSummary Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE’s late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01’s regulatory approval and commercialization as a first-in-class oral therapy. A strong cash position post-offering supports Phase 3 completion; execution on VDPHL01 is central to valuation and future stock momentum. Read the full article on Seeking Alpha
공시 • Feb 10Veradermics, Incorporated Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair LossVeradermics, Incorporated announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this milestone marks the completion of enrollment across both Phase 3 clinical trials of VDPHL01 in males, encompassing more than 1,000 participants. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements regarding the timing of completion of and data from the Phase 3 clinical trials for VDPHL01 for thetreatment of male and female pattern hair loss; the release profile of VDPHL01 and whether the release profile will achieve its intended effect; whether Veradermics will successfully file a new drug application for VDPHL01; and the projected size of the market for pattern hair loss treatments. Veradermics' anticipation that its success will depend on the approval and successful commercialization of VDPHL01, which is its lead product candidate, and if Veradermics is unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any other current or future product candidates, or experience significant delays in doing so, its business will be materially harm; risks related to preclinical and clinical development and that results of earlier studies and trials may not be predictive of future preclinical studies or clinical trial results; the risk that Veradermics may encounter substantial delays in preclinical and clinical trials, or may not be able to conduct or complete preclinical or clinical trials on the expected timelines, if at all; the risk that the U.S. Food and Drug Administration does not conclude that VDPHL01 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for VDPHL01 under Section 505(b)(2") are not as Veradermics expects, the approval pathway for those product candidates takes longer or costs more than anticipated; the risk that adverse events or undesirable side effects are caused by Veradermics' product candidates; competition from other companies; risks related to developing Veradermics' sales, marketing and distribution capability; the risk that even if Veradermics obtains regulatory approval for VDPHL01 or any other product candidates, such products may fail to achieve market acceptance; the risk that the commercial opportunity for VDPHL01 or Any other current or future product candidates may be smaller than Veradermics expects; the cash-pay healthcare market for VDPHL01 may limit Veradermics' ability to increase sales or achieve profitability; risks relating to effectively maintaining, promoting and enhancing Veradermics' reputation and VDPHL01 brand recognition in a cost-effective manner; risks related to Veradermics' need to grow its organization; the ability of Veradermics to successfully execute its intellectual property strategy for VDPHL01 and risks related to Veradermic' need to grow its organization. the ability of Veradermic to successfully execute its intellectual property strategies for VDPHL01 and risk related to Veradermics's ability to obtain and maintain sufficient intellectual property protection for VDPHL01 and other current and any future product candidates and other proprietary technologies; risks related to ongoing regulatory obligations for any approved products; risks related to Verader mics' reliance on third parties for the manufacture of drug or biological substances for preclinical studies and clinical trials and expectations that Veradermics will continue to do so for commercialization of any product candidates that are approved for marketing; risks related to VeraderMics' reliance and expected continued reliance on third parties to conduct preclinical studies and clinical trials; global macro conditions; global macro and regulatory obligations for any approved products.
공시 • Feb 04Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million.Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,077,647 Price\Range: $17 Transaction Features: Sponsor Backed Offering